Abstract
Systemic lupus erythematosus (SLE) is prototype of autoimmune disease with many immunological impairments and various clinical manifestation. In 2014 was approved the first biological drug for treatment of SLE, belimumab, and more of biological drugs are in clinical study phase.
The most promising seems the interaction with B lymphocytes (rituximab) directly or indirectly through costimulatory molecules (belimumab, blisibimod, tabalumab, ataciciept and others. This papers present the short review of those above and their role in therapy of SLE.